Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in hypertensive emergency-associated atypical hemolytic uremic syndrome
2022-002329-84Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in atypical hemolytic uremic syndrome (aHUS) comparing Eculizumab plus standard of care blood pressure control with Standard of care blood pressure control (2 arms). Primary endpoint: 6-month response to therapy. Started Oct 2024; status: active.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2022-002329-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002329-84.